

# Genzyme Corporation (GENZ)

## Analyst Schedule

(Unaudited, amounts in thousands, except percentage amounts)

	Q3-08	Q4-08	Q1-09	Q2-09	Q3-09	Q3-09 vs. Q3-08 % B/(W)	FY 2007	FY 2008	YTD 09/30/09
<b>Total revenues:</b>									
<b>Genetic Diseases</b>									
Cerezyme	\$ 309,280	\$ 306,034	\$ 295,970	\$ 298,087	\$ 93,599	(70%)	\$ 1,133,153	\$ 1,238,977	\$ 687,656
Fabrazyme	125,619	125,558	122,201	134,302	115,161	(8%)	424,284	494,260	371,664
Myozyme	76,663	74,967	67,392	79,273	85,980	12%	200,728	296,176	232,645
Aldurazyme	38,236	37,579	36,837	39,190	40,331	5%	-	151,664	116,358
Other Genetic Diseases	11,367	14,039	14,650	17,301	19,217	69%	8,314	45,615	51,168
Total Genetic Diseases product and service revenue	561,165	558,177	537,050	568,153	354,288	(37%)	1,766,479	2,226,692	1,459,491
R&D Revenue	-	-	-	-	-		1,059	-	-
<b>Total Genetic Diseases</b>	<b>561,165</b>	<b>558,177</b>	<b>537,050</b>	<b>568,153</b>	<b>354,288</b>	<b>(37%)</b>	<b>1,767,538</b>	<b>2,226,692</b>	<b>1,459,491</b>
<b>Cardiomatabolic and Renal</b>									
Renagel and Renvela (including Sevelamer)	170,992	169,476	170,599	175,398	181,702	6%	602,670	677,729	527,699
Hectorol	33,825	34,400	33,030	28,981	36,869	9%	115,708	128,153	98,880
Subtotal	204,817	203,876	203,629	204,379	218,571	7%	718,378	805,882	626,579
Thyrogen	38,153	37,062	38,826	42,860	41,691	9%	113,587	148,448	123,377
Other Cardiomatabolic and Renal	573	496	494	753	742	29%	103	1,653	1,989
Total Cardiomatabolic and Renal product and service revenue	243,543	241,434	242,949	247,992	261,004	7%	832,068	955,983	751,945
R&D revenue	56	27	13	8	156	179%	1,200	200	177
<b>Total Cardiomatabolic and Renal</b>	<b>243,599</b>	<b>241,461</b>	<b>242,962</b>	<b>248,000</b>	<b>261,160</b>	<b>7%</b>	<b>833,268</b>	<b>956,183</b>	<b>752,122</b>
<b>Biosurgery</b>									
Synvisc	67,513	68,512	63,171	82,417	87,526	30%	242,319	263,094	233,114
Sepra products	33,001	35,278	34,304	36,038	37,831	15%	104,318	133,663	108,173
Other Biosurgery	21,787	20,908	21,485	20,002	19,643	(10%)	74,673	91,698	61,130
Total Biosurgery product and service revenue	122,301	124,698	118,960	138,457	145,000	19%	421,310	488,455	402,417
R&D revenue	661	563	562	870	647	(2%)	5,337	2,645	2,079
<b>Total Biosurgery</b>	<b>122,962</b>	<b>125,261</b>	<b>119,522</b>	<b>139,327</b>	<b>145,647</b>	<b>18%</b>	<b>426,647</b>	<b>491,100</b>	<b>404,496</b>
<b>Hematologic Oncology</b>									
Total Hematologic Oncology product and service revenue	26,328	27,437	34,423	55,078	87,982	234%	69,927	102,899	177,483
R&D revenue	7,726	15,104	8,775	5,918	7	(100%)	18,601	36,148	14,700
<b>Total Hematologic Oncology</b>	<b>34,054</b>	<b>42,541</b>	<b>43,198</b>	<b>60,996</b>	<b>87,989</b>	<b>158%</b>	<b>88,528</b>	<b>139,047</b>	<b>192,183</b>
<b>Other</b>									
Genetic/Diagnostics product and service revenue	121,163	124,840	129,194	132,955	133,748	10%	410,917	477,614	395,897
Transplant product and service revenue	47,784	50,723	52,666	56,060	55,604	16%	174,826	192,200	164,330
Other product and service revenue	28,598	30,252	23,501	22,423	18,496	(35%)	108,577	119,155	64,420
Total Other product and service revenue	197,545	205,815	205,361	211,438	207,848	5%	694,320	788,969	624,647
R&D revenue	959	805	778	596	582	(39%)	3,218	3,048	1,956
<b>Total Other</b>	<b>198,504</b>	<b>206,120</b>	<b>206,139</b>	<b>212,034</b>	<b>208,430</b>	<b>5%</b>	<b>697,538</b>	<b>792,017</b>	<b>626,603</b>
<b>Total revenues</b>	<b>\$ 1,160,284</b>	<b>\$ 1,173,560</b>	<b>\$ 1,148,871</b>	<b>\$ 1,228,510</b>	<b>\$ 1,057,514</b>	<b>(9%)</b>	<b>\$ 3,813,519</b>	<b>\$ 4,605,039</b>	<b>\$ 3,434,895</b>

All amounts herein are presented in accordance with GAAP and are provided for quantitative analysis only and should be read in conjunction with the text of the Earnings Release and our audited financial statements filed with the Securities and Exchange Commission. Please refer to our Form 10-Q's and Form 10-K's for an in-depth discussion and analysis of our results of operations and financial position and for detailed information regarding specific material transactions in a particular period.